DDInter1398 DDInter1435
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Pasireotide {u} (Compound) resembles {v} (Compound) Terlipressin
Pasireotide {u} (Compound) binds {v} (Gene) SSTR5
Pasireotide {u} (Compound) is included by {v} (Pharmacologic Class) Somatostatin Receptor Agonists
Pasireotide {u} (Compound) causes {v} (Side Effect) Abdominal pain
Pasireotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pasireotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoprolol
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Protriptyline
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Pasireotide (Compound) resembles Terlipressin (Compound)
Pasireotide (Compound) binds SSTR5 (Gene)
Pasireotide (Compound) is included by Somatostatin Receptor Agonists (Pharmacologic Class)
Pasireotide (Compound) causes Abdominal pain (Side Effect)
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Doravirine
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol
Pasireotide may lead to a major life threatening interaction when taken with Protriptyline
Pasireotide may lead to a major life threatening interaction when taken with Fingolimod